U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Cover of StatPearls

StatPearls [Internet].

Show details

Tinea Versicolor

; .

Author Information and Affiliations

Last Update: August 8, 2022.

Continuing Education Activity

Pityriasis versicolor, also known as tinea versicolor, is a common, benign, superficial fungal infection of the skin. Clinical features of pityriasis versicolor include either hyperpigmented or hypopigmented finely scaled macules. The most frequently affected sites are the trunk, neck, and proximal extremities. This activity reviews the evaluation and management of pityriasis versicolor and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.


  • Describe the epidemiology of pityriasis versicolor.
  • Explain the evaluation for pityriasis versicolor.
  • Outline treatment considerations for pityriasis versicolor.
  • Summarize the importance of enhancing care coordination among the interprofessional team to ensure proper evaluation and management of pityriasis versicolor.
Access free multiple choice questions on this topic.


Pityriasis versicolor, also known as tinea versicolor, is a frequent, benign, superficial fungal infection of the skin. It belongs to Malassezia-related diseases. Clinical features of pityriasis versicolor include either hyperpigmented or hypopigmented finely scaly macules. The most frequently affected sites are the trunk, neck, and proximal extremities.[1][2][3] The diagnosis of pityriasis versicolor is often made on clinical grounds alone. The ultraviolet black light and the microscopic examination of scales soaked in potassium hydroxide may be helpful in doubtful cases. Pityriasis versicolor responds well to induction therapy. However, long-term maintenance treatment often is required because of high recurrence rate.


Pityriasis versicolor is caused by Malassezia, a dimorphic lipophilic fungus, also known as Pityrosporum. It is a component of normal skin flora. To date, 14 species of Malassezia have been identified. [3]The main species isolated in pityriasis versicolor are Malassezia furfur, Malassezia globosa, Malassezia sympodialis.


Pityriasis versicolor has been reported worldwide, but it is more common in warm and humid conditions. The prevalence is as high as 50% in tropical countries and as low as 1.1% in cold climates such as Sweden. Pityriasis versicolor occurs more frequently in adolescents and young adults probably due to the increase of sebum production by the sebaceous glands which allow for a more lipid-rich environment in which Malassezia can grow. Pityriasis versicolor affects men and women equally and no specific ethnic predominance has been noted.[4][5]


Malassezia is commensal of healthy skin, and it is most common in oily areas such as the face, scalp, and back. However, Malassezia can cause pityriasis versicolor when it converts to its pathogenic filamentous form. Factors that lead to this pathogenic conversion include a genetic predisposition, environmental conditions such as heat and humidity, immunodeficiency, pregnancy, oily skin, and application of oily lotions and creams.


A skin biopsy is not required to confirm a diagnosis, but if it is performed, histological findings include hyperkeratosis, acanthosis, and a mild superficial, perivascular infiltrate in the dermis. Fungal elements are localized almost exclusively within the stratum corneum and can often be visualized even in sections stained with hematoxylin-eosin. Both spores and hyphae of Malassezia are present and are often likened to spaghetti and meatballs. Periodic acid-Schiff stain may improve recognition of the fungus.

History and Physical

Patients with pityriasis versicolor present with multiple, well-demarcated, oval, finely scaling patches or plaques. Skin lesions may be hypopigmented, hyperpigmented, or erythematous and occasionally become confluent and widespread. The fine scale may not be readily apparent on the lesions, but it is easily provoked when the affected skin is stretched or scraped. The distribution of affected skin reflects the lipophilic nature of the fungus since the seborrheic areas (trunk, neck, and/or arms) are predominantly involved. The face also may be affected, particularly in children. Pityriasis versicolor skin lesions are usually asymptomatic or slightly pruritic. However, severe pruritus can be present in very warm and humid conditions.


Diagnosis of pityriasis versicolor is usually easily made on the basis of its characteristic clinical presentation (hyperpigmented or hypopigmented, finely scaling patches or plaques).[6][7][8]

The ultraviolet black light (Wood lamp) may help to demonstrate the coppery-orange fluorescence of pityriasis versicolor.

The diagnosis is confirmed by microscopic examination of scales soaked in potassium hydroxide examination, which demonstrates the typical grape-like clusters of yeast cells and long hyphae. Since the standard potassium-hydroxide mount lacks a color contrast, methylene blue stain, ink blue stain, or Swartz-Medrik stain may be added to visualize better.

Malassezia species are known to be difficult to grow in the laboratory as they require fastidious culture conditions.

Treatment / Management

Patients should be informed that the causative agent of pityriasis versicolor is a commensal fungal inhabitant of the normal skin flora, and therefore the disease is not considered to be contagious. In addition, pityriasis versicolor does not lead to either permanent scarring or pigmentary disorders. However, in many cases, disease recurrence may occur despite effective treatment.[9][10][11]

Pityriasis versicolor may be treated effectively with topical and/or systemic agents.

Topical medications are considered the first-line therapy for pityriasis versicolor. Topical treatments are divided into nonspecific antifungal agents (sulfur plus salicylic acid,  selenium sulfide 2.5%, and zinc-pyrithione) that primarily remove dead tissue and prevent further invasion, and specific antifungal drugs, that have fungicidal or fungistatic effects. Antifungal agents include imidazole (clotrimazole 1%, ketoconazole 2%, econazole, isoconazole, miconazole), ciclopirox olamine 1% , and allylamine (terbinafine 1%). Galenic forms such as sprays or foaming solutions in shampoo are preferable to creams because creams are oilier and more difficult to apply, especially in widespread areas. Ketoconazole is the most common topical treatment used to treat pityriasis versicolor. It can be applied as a  cream (twice daily for 15 days) or in a foaming solution (single dose).

Oral medications are viewed as a second-line of treatment for pityriasis versicolor in the event of widespread, severe, recalcitrant or recurrent cases. Systemic therapies include itraconazole (200 mg daily for seven days) and fluconazole (150 to 300 mg weekly dose for 2 to 4 weeks) that are preferred to oral ketoconazole which is no longer approved due to its potential hepatotoxic sides effects. Oral terbinafine is not effective in the treatment of pityriasis versicolor.

In cases of recurrent pityriasis versicolor, maintenance therapy may be necessary. Topical prophylactic treatment can be used. However, systemic antifungal agents are preferred since they are less time-consuming and ensure better compliance. Many studies have been conducted to identify the best prophylactic regimen.

Differential Diagnosis

Pityriasis versicolor may be confused with various conditions:

  • Pityriasis rosea
  • Tinea corporis
  • Vitiligo
  • Pityriasis alba
  • Confluent reticulated papillomatosis of Gougerot and Carteaud
  • Postinflammatory hypo- and hyperpigmentation
  • Seborrheic dermatitis
  • Guttate psoriasis
  • Tinea corporis
  • Nummular eczema
  • Secondary syphilis
  • Mycosis fungoides


Pityriasis versicolor is benign and noncontagious since the causative fungal pathogen is commensal of normal skin. Oral and topical antifungal agents are effective; however, disease recurrence is common and may have an impact on a patient's quality of life. Therefore, preventive measures should be taken. Also, patients must be reminded that pigmentary changes may take weeks to months to clear, even if the fungus is eradicated.

Pearls and Other Issues

Pityriasis versicolor is a benign but commonly recurrent superficial fungal infection of the skin. Therefore, patients need effective follow-up care to implement a relapse prevention strategy.

Enhancing Healthcare Team Outcomes

Tinea versicolor is a relatively common skin disorder that may be encountered by the nurse practitioner, internist, dermtologist and primary care physician. The diagnosis is usually made on clinical features but does require clinical acumen. The rash is benign and may spontaneously disappear.

Patients should be informed that the causative agent of pityriasis versicolor is a commensal fungal inhabitant of the normal skin flora, and therefore the disease is not considered to be contagious. In addition, pityriasis versicolor does not lead to either permanent scarring or pigmentary disorders. However, in many cases, disease recurrence may occur despite effective treatment. An interprofessional team of a nurse and clinician should provide patient education which will decrease their anxiety and provide the best patient outcome.

The outcomes in most patients are excellent.[12][13] (Level V)

Review Questions



Pityriasis Versicolor DermNet New Zealand

Pityriasis Versicolor Contributed by Dr


Pityriasis Versicolor Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India


Brandi N, Starace M, Alessandrini A, Piraccini BM. Tinea versicolor of the neck as side effect of topical steroids for alopecia areata. J Dermatolog Treat. 2019 Dec;30(8):757-759. [PubMed: 30668183]
Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatolog Treat. 2019 Dec;30(8):760-771. [PubMed: 30668185]
Diongue K, Kébé O, Faye MD, Samb D, Diallo MA, Ndiaye M, Seck MC, Badiane AS, Ranque S, Ndiaye D. MALDI-TOF MS identification of Malassezia species isolated from patients with pityriasis versicolor at the seafarers' medical service in Dakar, Senegal. J Mycol Med. 2018 Dec;28(4):590-593. [PubMed: 30340859]
Alvarado Z, Pereira C. Fungal diseases in children and adolescents in a referral centre in Bogota, Colombia. Mycoses. 2018 Aug;61(8):543-548. [PubMed: 29601109]
De Luca DA, Maianski Z, Averbukh M. A study of skin disease spectrum occurring in Angola phototype V-VI population in Luanda. Int J Dermatol. 2018 Jul;57(7):849-855. [PubMed: 29573271]
Errichetti E, Stinco G. Dermoscopy in General Dermatology: A Practical Overview. Dermatol Ther (Heidelb). 2016 Dec;6(4):471-507. [PMC free article: PMC5120630] [PubMed: 27613297]
Prohic A, Jovovic Sadikovic T, Krupalija-Fazlic M, Kuskunovic-Vlahovljak S. Malassezia species in healthy skin and in dermatological conditions. Int J Dermatol. 2016 May;55(5):494-504. [PubMed: 26710919]
Rosen T. Mycological Considerations in the Topical Treatment of Superficial Fungal Infections. J Drugs Dermatol. 2016 Feb;15(2 Suppl):s49-55. [PubMed: 26885799]
Gupta AK, Foley KA. Antifungal Treatment for Pityriasis Versicolor. J Fungi (Basel). 2015 Mar 12;1(1):13-29. [PMC free article: PMC5770013] [PubMed: 29376896]
Gupta AK, Lyons DC. Pityriasis versicolor: an update on pharmacological treatment options. Expert Opin Pharmacother. 2014 Aug;15(12):1707-13. [PubMed: 24991691]
Hawkins DM, Smidt AC. Superficial fungal infections in children. Pediatr Clin North Am. 2014 Apr;61(2):443-55. [PubMed: 24636655]
Browning JC. An update on pityriasis rosea and other similar childhood exanthems. Curr Opin Pediatr. 2009 Aug;21(4):481-5. [PubMed: 19502983]
Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ, Elewski BE, Elgart ML, Jacobs PH, Lesher JL, Scher RK. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9. [PubMed: 8642095]
Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin. 2003 Jul;21(3):413-29, v-vi. [PubMed: 12956196]
Jena DK, Sengupta S, Dwari BC, Ram MK. Pityriasis versicolor in the pediatric age group. Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):259-61. [PubMed: 16394435]
Faergemann J, Fredriksson T. Experimental infections in rabbits and humans with Pityrosporum orbiculare and P. ovale. J Invest Dermatol. 1981 Sep;77(3):314-8. [PubMed: 7264365]

Disclosure: Mehdi Karray declares no relevant financial relationships with ineligible companies.

Disclosure: William McKinney declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK482500PMID: 29494106


  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...